We believe that to finally resolve the issue of the ability of JNK inhibitors to protect the BBB during I/R, it is necessary to obtain experimental evidence of the efficacy of JNK inhibitors in a situation close to the clinical one, namely, when the test substance is administered during and/or after an episode of ischemia, indicating the timing of administration. This evidence concerns the gene MAPK8 and ischemia.